Tectonic Therapeutic, Inc.（TECX）股价、财务与研究

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

47/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

39

Expensive

动量

63

Gaining

情绪

61

Bullish

风险韧性

56

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Alise S. Reicin
上市以来: 2018年6月21日
雇员: 60

市场位置

成交量: 18.86万; 0.93× 平均值
平均成交量: 20.33万; 日均成交量
市值: 7.1亿 USD
贝塔: 0.22; 市场参考 1

财报历史与展望

EPS超预期率: 64%; 超预期7次、低于预期4次、符合预期0次
平均EPS意外幅度: +1.33%; 11 类似报告
最新每股收益结果: -1.18; 预期-1.35 · 超预期12.59%

EPS：实际值与预期值

近期已公布业绩

实际值预期值

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$78.00

上涨空间 107.28%

过去 12 个月12个月预测最高：US$81.00平均的：US$78.00最低：US$75.00

评级分布

5项评级

强力买入120%

买入480%

持有00%

卖出00%

强力卖出00%

TECX 消息

globenewswire.com2026年8月6日

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1…

阅读源码

globenewswire.com2026年6月10日

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191…

阅读源码

globenewswire.com2026年6月10日

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic…

阅读源码